Oracle denies delaying OpenAI data centers to 2028 due to shortages Investors worried about Oracle's debt-fueled AI infrastructure buildout Market sensitive to AI delays, scrutinizing spending payoffs ...

Oracle (ORCL) shares erased some losses on Friday after the company pushed back on a report that it was delaying some data centers tied to OpenAI (OPENAI). Oracle initially declined to comment on the ...

Oracle has 274 healthcare customers for its clinical AI agent, a number that “continues to rise daily,” the company said. The software giant touted its healthcare offerings during a Dec. 10 earnings ...

Oracle has reportedly delayed some of its data center projects set for OpenAI workloads by as much as a year. The company made the move to delay projects from 2027 to 2028, Bloomberg reports, mostly ...

(Bloomberg) --Oracle Corp. has pushed back the completion dates for some of the data centers it’s developing for the artificial intelligence model developer OpenAI to 2028 from 2027, according to ...

Investing.com -- Oracle Corporation (NYSE:ORCL) stock fell 5% on Friday following a Bloomberg report that the company has delayed the completion of data centers for OpenAI to 2028, a year later than ...

Oracle's 2052 bonds are offering a rare 7% yield. Read about the risks and if they're right for income-focused investors.

Cal Poly saw the highest enrollment in what appears to be university history this year, with more than 23,000 students flocking to the San Luis Obispo campus in September. According to data released ...

The World Economic Outlook (WEO) database contains selected macroeconomic data series from the statistical appendix of the World Economic Outlook report, which presents the IMF staff's analysis and ...

The MarketWatch News Department was not involved in the creation of this content. LAKELAND, Fla., Dec. 15, 2025 /PRNewswire/ -- Florida Polytechnic University's undergraduate computer science and data ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Oracle stock slumped after it reported disappointing revenues on Wednesday alongside a $15bn increase in its ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...